• Willing to follow the treatment protocol and visit schedule, and participate in the study with the ICF signed;

• ≥ 18 years of age on the day of ICF signing, regardless of gender.

• With ALK-positive advanced inoperable NSCLC and having disease progression or intolerance after continuous treatment with second-generation ALK inhibitors;

• Providing prior ALK positive test results at screening;

• Patients could have metastases to central nervous system at screening if the condition is asymptomatic, stable or completely recovered;

• Drug discontinuation for ≥ 5 half-lives prior to the first dose for subjects previously treated with ALK inhibitors;

• At least one measurable lesion;

• An ECOG PS score within 0-2;

• Adequate bone marrow, liver, kidney, coagulation and pancreatic functions;

⁃ Expected survival ≥ 3 months;

⁃ Willing to take effective contraceptive measures (for men of reproductive potential and women of reproductive age only) from ICF signing to 6 months after administration of the investigational drug. Women of reproductive age include women before menopause and within 2 years after menopause. Those women must have a negative pregnancy test ≤ 7 days prior to the first dose of the investigational drug.